Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Cue Biopharma, Inc. (CUE : NSDQ)

• Company Description    Cue Biopharma, Inc. is an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. Cue Biopharma, Inc. is headquartered in Cambridge, Massachusetts. Number of Employees: 29

• Price / Volume Information    Yesterday's Closing Price: $18.66 Daily Weekly Monthly 20 Day Moving Average: 196,983 shares Shares Outstanding: 7.26 (millions) Market Capitalization: $135.55 (millions) Beta: 2.62 52 Week High: $45.50 52 Week Low: $4.97 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -43.20% -42.60% 12 Week -38.62% -40.12% Year To Date 103.46% 83.99%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 40 GUEST STREET - BOSTON,MA 02135 USA ph: 617-949-2680 fax: - ir@cuebio.com http://www.cuebiopharma.com

• General Corporate Information    Officers Usman Azam - President; Chief Executive Officer and Director Lucinda Warren - Chief Financial and Business Officer Peter A. Kiener - Director Jill Marie Broadfoot - Director Pamela Garzone - Director Peer Information Cue Biopharma, Inc. (CORR.) Cue Biopharma, Inc. (RSPI) Cue Biopharma, Inc. (CGXP) Cue Biopharma, Inc. (BGEN) Cue Biopharma, Inc. (GTBP) Cue Biopharma, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 22978P205 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/11/26 Share - Related Items Shares Outstanding: 7.26 Most Recent Split Date: 4.00 (0.03:1) Beta: 2.62 Market Capitalization: $135.55 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-2.83 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-21.79 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/11/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 42.24 Price/Cash Flow: - Price / Sales: 3.60 EPS Growth vs. Year Ago Period: -410.97% vs. Previous Quarter: -1,178.70% Sales Growth vs. Year Ago Period: 166.66% vs. Previous Quarter: 38.53% ROE 09/30/26 - - 06/30/26 - -620.06 03/31/26 - -98.30 ROA 09/30/26 - - 06/30/26 - -291.15 03/31/26 - -53.69 Current Ratio 09/30/26 - - 06/30/26 - 1.25 03/31/26 - 3.57 Quick Ratio 09/30/26 - - 06/30/26 - 1.25 03/31/26 - 3.57 Operating Margin 09/30/26 - - 06/30/26 - -261.82 03/31/26 - -59.65 Net Margin 09/30/26 - - 06/30/26 - -435.83 03/31/26 - -59.65 Pre-Tax Margin 09/30/26 - - 06/30/26 - -434.50 03/31/26 - -58.12 Book Value 09/30/26 - - 06/30/26 - 0.44 03/31/26 - 6.64 Inventory Turnover 09/30/26 - - 06/30/26 - - 03/31/26 - - Debt-to-Equity 09/30/26 - - 06/30/26 - 0.00 03/31/26 - 0.00 Debt-to-Capital 09/30/26 - - 06/30/26 - 0.00 03/31/26 - 0.00

Powered by Zacks Investment Research ©